Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ICUCW
Upturn stock ratingUpturn stock rating

LMF Acquisition Opportunities Inc (ICUCW)

Upturn stock ratingUpturn stock rating
$0.03
Delayed price
Profit since last BUY-25%
upturn advisory
WEAK BUY
BUY since 13 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: ICUCW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -34.62%
Avg. Invested days 23
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 45861
Beta -0.99
52 Weeks Range 0.01 - 0.24
Updated Date 02/17/2025
52 Weeks Range 0.01 - 0.24
Updated Date 02/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -6552.94%

Management Effectiveness

Return on Assets (TTM) -292.92%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 4384909
Shares Outstanding -
Shares Floating 4384909
Percent Insiders -
Percent Institutions -

AI Summary

LMF Acquisition Opportunities Inc. (NASDAQ: LMF.U) - Comprehensive Overview

Company Profile:

History and Background: LMF Acquisition Opportunities Inc. is a blank check company formed in February 2021 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Core Business Areas: As a SPAC (Special Purpose Acquisition Company), LMF doesn't have any existing business operations. Its primary focus is to identify and acquire a target company within a specified timeframe. The company's target industry is not specified, leaving it open to potential acquisitions across various sectors.

Leadership Team and Corporate Structure:

  • CEO and Chairman: Luis Medina
  • CFO and Treasurer: Kevin J. Smith
  • Executive Vice President and Secretary: Daniel R. McClary

The company's board of directors consists of five members, including Luis Medina, Andrew T. Cohen, Robert W. Grady, Richard S. Kramer, and Thomas J. Wilson.

Top Products and Market Share:

LMF Acquisition Opportunities Inc. does not have any products or services, as it is a pre-acquisition company.

Total Addressable Market:

As the company hasn't yet acquired a target, its total addressable market is undefined. However, considering its focus on technology-related businesses, the potential market size could be substantial.

Financial Performance:

LMF has not generated any revenue or earnings as it is a pre-revenue company.

Dividends and Shareholder Returns:

Since the company hasn't commenced operations, it hasn't paid any dividends or generated any shareholder returns.

Growth Trajectory:

LMF's growth trajectory will depend on the target company it acquires. The company's future success will be determined by the performance of the acquired business and its ability to capitalize on market opportunities.

Market Dynamics:

The SPAC market is experiencing a slowdown after a period of rapid growth. However, there is still significant interest from investors in quality SPACs with strong management teams and promising acquisition targets.

Competitors:

LMF competes with other SPACs looking to acquire technology-related businesses.

Key Competitors:

  • CIIC Merger Corp. (CIIC)
  • GO Acquisition Corp. (GOAC)
  • Social Capital Hedosophia Holdings VI (IPOF)

Recent Acquisitions:

LMF has not completed any acquisitions to date.

AI-Based Fundamental Rating:

Based on publicly available information, it is not possible to provide an AI-based fundamental rating for LMF. Such a rating would require detailed analysis of the company's financial statements, management team, and potential acquisition targets, which are currently unavailable.

Sources and Disclaimers:

This analysis is based on information obtained from LMF Acquisition Opportunities Inc.'s SEC filings and press releases. Investors should conduct their own due diligence before making any investment decisions.

Disclaimer:

This information is provided for educational purposes only and should not be considered as financial advice.

Please note: This analysis is based on publicly available information as of today's date, October 26, 2023. Any information published after this date may not be reflected in this analysis.

About LMF Acquisition Opportunities Inc

Exchange NASDAQ
Headquaters Denver, CO, United States
IPO Launch date 2021-03-18
CEO, President & Executive Director Mr. Eric Schlorff
Sector Healthcare
Industry Biotechnology
Full time employees 12
Full time employees 12

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​